Table 2.
Association of Aldosterone with Death, ESRD and Cardiovascular Outcomes in the CRIC Study
| Outcome Variable | Aldosterone Quartiles | Linear model | ||||
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | Per SD | P-value | |
| Death | ||||||
| Annual event rate (# events/# at risk) | 2.7% (142/967) | 2.6% (133/966) | 3.1% (156/967) | 3.0% (156/966) | ||
| Unadjusted; HR (95% CI) | 1.00 (ref) | 0.95 (0.75, 1.21) | 1.14 (0.91, 1.44) | 1.09 (0.87, 1.37) | 1.03 | 0.48 |
| Adjusted*; HR (95% CI) | 1.00 (ref) | 0.80 (0.62, 1.03) | 0.92 (0.72, 1.18) | 0.89 (0.69, 1.15) | 1.00 | 0.98 |
| ESRD | ||||||
| Annual event rate (# events/# at risk) | 3.0% (145/967) | 3.5% (167/966) | 4.6% (214/967) | 4.6% (217/966) | ||
| Unadjusted; HR (95% CI) | 1.00 (ref) | 1.19 (0.95, 1.48) | 1.58 (1.28, 1.95) | 1.58 (1.28, 1.95) | 1.14 | <0.001 |
| Adjusted*; HR (95% CI) | 1.00 (ref) | 0.96 (0.75, 1.22) | 1.08 (0.85, 1.38) | 1.16 (0.91, 1.48) | 1.06 | 0.15 |
| + FGF-23; HR (95% CI) | 1.00 (ref) | 0.94 (0.74, 1.20) | 1.08 (0.85, 1.37) | 1.17 (0.92, 1.48) | 1.07 | 0.11 |
| CHF | ||||||
| Annual event rate (# events/# at risk) | 1.2% (40/643) | 1.2% (39/643) | 1.5% (50/643) | 1.8% (58/642) | ||
| Unadjusted; HR (95% CI) | 1.00 (ref) | 1.01 (0.65, 1.58) | 1.31 (0.86, 1.98) | 1.49 (1.00, 2.24) | 1.18 | 0.0098 |
| Adjusted†; HR (95% CI) | 1.00 (ref) | 0.82 (0.51, 1.32) | 1.03 (0.64, 1.65) | 1.36 (0.87, 2.13) | 1.21 | 0.012 |
| Combined Atherosclerotic Endpoint | ||||||
| Annual event rate (# events/# at risk) | 1.2% (39/643) | 1.2% (40/643) | 1.5% (47/643) | 1.6% (51/642) | ||
| Unadjusted; HR (95% CI) | 1.00 (ref) | 1.05 (0.67, 1.63) | 1.24 (0.81, 1.90) | 1.34 (0.88, 2.03) | 1.05 | 0.55 |
| Adjusted†; HR (95% CI) | 1.00 (ref) | 0.94 (0.59, 1.50) | 0.95 (0.59, 1.52) | 1.28 (0.81, 2.02) | 1.04 | 0.62 |
SD, standard deviation; HR, hazard ratio; Cl, confidence interval; ESRD, end stage renal disease; FGF, fibroblast growth factor; CHF, congestive heart failure.
adjusted for age, sex, race, clinical center, diabetes, systolic blood pressure, history of cardiovascular disease, eGFR, urinary protein (24 hour sample), urinary sodium excretion (24 hour sample), urinary sodium to potassium ratio (24 hour sample), hemoglobin, serum albumin, serum potassium, ACE inhibitor/ARB use, mineralocorticoid receptor blocker use, loop diuretic use, statin, and log NT-pro BNP.
adjusted for age, sex, race, clinical center, diabetes, systolic blood pressure, eGFR, urinary protein (24 hour sample), urinary sodium excretion (24 hour sample), urinary sodium to potassium ratio (24 hour sample), hemoglobin, serum albumin, serum potassium, ACE inhibitor/ARB use, mineralocorticoid receptor blocker use, loop diuretic use, statin, and log NT-pro BNP.